Biorelease Corp. announced Tuesday that it has launchedcommercial sales of Erythrogen, its cell culture additive.
The Salem, N.H., company (NASDAQ:BREL) has shipped"thousands of units" of the cell-growth promoter to a major cellculture media formulator, said R. Bruce Reeves, chief operatingofficer of Biorelease.
Erythrogen is derived from bovine blood, and as a cell cultureadditive has been shown to enhance cell growth rates, densityand viability. Biorelease is marketing Erythrogen to academicand industrial researchers -- especially those involved inculturing insect cells -- as well as sourcing the product on abulk basis to cell culture supply companies.
(c) 1997 American Health Consultants. All rights reserved.